Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Cell Dev. Biol.

Sec. Cancer Cell Biology

Volume 13 - 2025 | doi: 10.3389/fcell.2025.1677290

This article is part of the Research TopicInnovative Approaches to Combat Tumorigenesis and Drug Resistance: From Molecular Insights to Therapeutic AdvancementsView all articles

Integrated machine learning analysis of 30 cell death patterns identifies a novel prognostic signature in glioma

Provisionally accepted
Minhao  HuangMinhao Huang1Kai  ZhaoKai Zhao1Yongtao  YangYongtao Yang1Kexin  MaoKexin Mao2Hangyu  MaHangyu Ma1Tingting  WuTingting Wu1Guolin  ShiGuolin Shi1Wenhu  LiWenhu Li1Yan  LiYan Li1Ruiqi  PengRuiqi Peng2Ying  ChengYing Cheng2Ninghui  ZhaoNinghui Zhao1*
  • 1The Second Affiliated Hospital of Kunming Medical University, Kunming, China
  • 2Yunnan University, Kunming, China

The final, formatted version of the article will be published soon.

Background: Glioma heterogeneity and therapeutic resistance are closely linked to dysregulated programmed cell death (PCD). While individual PCD pathways have been studied, the integrated network of multi-modal PCD interactions and their clinical implications in glioma remain poorly understood. This study aims to decipher the interplay between 30 distinct PCD modalities and the immune microenvironment, developing a robust prognostic signature to guide therapy. Results: Integrated analysis of 2,743 public gliomas samples identified 428 cell death-associated differentially expressed genes, enriched in neuroactive ligand-receptor interactions and extracellular matrix regulation. Unsupervised clustering revealed distinct immune-activated and immune-silent patient subtypes. A pan-death prognostic signature (Cell-Death Score, CDS), constructed via multi-algorithm machine learning and optimized using CoxBoost to incorporate 25 key genes, demonstrated robust performance in training (1-/3-year AUC=0.894/0.943) and validation cohort (C-index=0.717), effectively stratifying high-risk patients (HR=3.21, p<0.0001). High-CDS patients displayed elevated tumor mutational burden, homologous recombination deficiency, and immune checkpoint expression, alongside enhanced sensitivity to 11 therapeutic agents, including gemcitabine. Single-cell trajectory analysis confirmed significant activation of model genes during glioma progression. A clinical nomogram integrating CDS, WHO grade and radiotherapy further improved prognostic utility. Based on in vitro cell line experiments, the expression profiles of 25 key genes demonstrated significant heterogeneity, with partial genes undetectable by qRT-PCR due to expression levels falling below detection thresholds. Among seven genes consistently detected across all four cell lines, tumor cell lines exhibited significantly upregulated expression relative to normal astrocyte counterparts. RNA-seq analysis revealed effective detection of 24/25 key genes in seven paired tumor/adjacent tissue samples, with 20 genes showing higher mean expression in tumor tissues. qRT-PCR validation confirmed upregulated trends for 12 detectable genes in tumor tissues. Spatial transcriptomic analysis further corroborated tumor region-specific overexpression of all 25 key genes compared to adjacent non-tumorous areas. Conclusion: The CDS signature unravels the molecular interplay between glioma cell death heterogeneity, immune dysregulation, and therapeutic resistance. This biomarker system provides both prognostic and therapeutic insights for precision oncology, paving the way for personalized combination therapies in glioma management.

Keywords: Glioma, programmed cell death, machine learning, immune microenvironment, drug sensitivity, Prognostic model

Received: 31 Jul 2025; Accepted: 08 Sep 2025.

Copyright: © 2025 Huang, Zhao, Yang, Mao, Ma, Wu, Shi, Li, Li, Peng, Cheng and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Ninghui Zhao, The Second Affiliated Hospital of Kunming Medical University, Kunming, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.